Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TaILOR: a randomised trial to compare the clinical and cost-effectiveness of a patient-initiated follow-up (PIFU) strategy compared to standard care pathways in people with inflammatory arthritis: a study protocol.

Trials·2026
Same author

Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY.

The Lancet. Rheumatology·2026
Same author

Is clonal haematopoiesis the missing link between lupus and cardiovascular disease?

Rheumatology (Oxford, England)·2026
Same author

Executive Summary: The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.

Rheumatology (Oxford, England)·2026
Same author

Silent patients, silent disease: misalignment in patient-initiated follow-up - Authors reply.

The Lancet. Rheumatology·2026
Same journal

Artificial Intelligence in Rheumatology: A Comprehensive Bibliometric Analysis and Current Scientific Mapping Research.

Mediterranean journal of rheumatology·2026
Same journal

Older Age, Steroid Exposure, and Digital Pitting Scars Predict Poor Outcomes in Scleroderma Renal Crisis: A 30-Year Retrospective Cohort Study.

Mediterranean journal of rheumatology·2026
Same journal

An Observational Case-Control Study of the Anti-Inflammatory Effects of Bromelain on Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus.

Mediterranean journal of rheumatology·2026
Same journal

Knowledge, Attitudes, and Clinical Experience with Cannabinoid Therapies: A Cross-Sectional Survey of Rheumatologists.

Mediterranean journal of rheumatology·2026
Same journal

Serum Sclerostin Correlates with ACPA Positivity in Post-Menopausal Women with Rheumatoid Arthritis: Data from a Cross-Sectional Case-Control Study in Greece.

Mediterranean journal of rheumatology·2026
Same journal

Regression and Disappearance of Accelerated Nodulosis with Adalimumab.

Mediterranean journal of rheumatology·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Giant Cell Myocarditis: Is It Time to Redeploy Cytokine Inhibitors?

Deepak Nagra1, Iyantha Sarindhi Kuruppurachchi2, Kaiyang Song1

  • 1Centre for Rheumatic Disease, King's College London - Centre for Rheumatic Disease, United Kingdom.

Mediterranean Journal of Rheumatology
|May 8, 2026
PubMed
Summary
This summary is machine-generated.

Giant cell myocarditis (GCM) is a rare, aggressive heart condition. Emerging treatments focus on T-cell and cytokine pathways, offering new hope for managing this life-threatening disease.

Keywords:
JAK inhibitionautoimmunecytokine inhibitorsgiant cell myocarditisinflammationmonoclonal antibody

More Related Videos

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Related Experiment Videos

Last Updated: May 9, 2026

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Area of Science:

  • Cardiology
  • Immunology
  • Pathology

Background:

  • Giant cell myocarditis (GCM) is a rare, aggressive T-lymphocyte-mediated cardiac disorder with high mortality.
  • Diagnosis is confirmed via endomyocardial biopsy, with cardiac MRI as a non-invasive tool.
  • GCM's rarity and coding issues limit epidemiological data and clinical trials.

Purpose of the Study:

  • To review current understanding and emerging therapeutic strategies for Giant Cell Myocarditis.
  • To highlight the potential of targeted immunotherapies in managing GCM.

Main Methods:

  • Review of existing literature on GCM diagnosis and treatment.
  • Analysis of emerging evidence for targeted therapies, including JAK inhibitors and cytokine inhibitors.

Main Results:

  • Conventional treatments show limited success; novel approaches target T-cell and cytokine pathways.
  • Tofacitinib demonstrates potential due to rapid immunomodulation and favorable pharmacokinetics.
  • Real-world data and international collaboration are crucial for defining optimal GCM treatment.

Conclusions:

  • Early cytokine inhibition represents a potential paradigm shift in GCM management.
  • Targeting specific immune pathways offers promising therapeutic avenues.
  • Further research and data collection are essential for improving outcomes in GCM.